You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK)與倍而達藥業訂立產品授權及商業化協議
格隆匯 03-09 22:38

格隆匯 3 月 9日丨石藥集團(01093.HK)公吿,公司全資附屬公司石藥(上海)有限公司("石藥上海")已與上海倍而達藥業有限公司("倍而達藥業")訂立產品授權及商業化協議,內容有關其產品BPI-7711膠囊(用於治療非小細胞肺癌不可逆的第三代小分子表皮生長因子受體酪氨酸激酶抑制劑(EGFR—TKI))獨家產品授權及商業化。

根據該協議,石藥上海將獲得BPI-7711膠囊獨家權利,以於中華人民共和國(包括香港特別行政區和澳門特別行政區,但不包括台灣地區)進行BPI-7711膠囊的商業化活動,並擁有BPI-1178膠囊(CDK4/6抑制劑)商業化授權的優先談判權。

與此同時,集團同意向倍而達藥業方面進行股權認購,首次認購金額人民幣2億元,須待若干先決條件獲達成後方可作實。

BPI-7711膠囊將於近期在中國提交產品上市申請。

董事會相信,該產品的引入將進一步豐富集團腫瘤產品線。集團強大的銷售及推廣能力,將加速推動該產品的商業化,滿足中國患者迫切的臨牀需求。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account